Fludarabine

製品コードS1491 別名:FaraA, Fludarabinum

Fludarabine化学構造

分子量(MW):285.23

Fludarabineは血管平滑筋細胞の中に一種のSTAT1活性阻害剤で、一種のDNA合成阻害剤です。

サイズ 価格 在庫  
JPY 18156.88 あり
JPY 13966.83 あり
JPY 44636.28 あり
JPY 67674.36 あり
JPY 139668.35 あり

カスタマーフィードバック(4)

  • ERK signaling regulates STAT1 phosphorylation, and pSTAT1 modulates MHC II expression in the spinal cord under BCP conditions. AG490 (5 μg in 10 μL), Fludarabine (10 μg in 10 μL), or U0126 (5 μg in 10 μL) was intrathecally injected into cancer-bearing rats once a day for 14 days, beginning immediately after carcinoma cell inoculation (n = 3 in each group). (A) Representative western blot showing pSTAT1ser727, total STAT1, pERK42/44, total ERK42/44, CIITA, MHC II RTIB, and b actin protein levels in the spinal cords of BCP rats.

    Brain Behav Immun, 2017, 60:161-173. Fludarabine purchased from Selleck.

    Imatinib mesylate (IM) in combination of fludarabine phosphate (F-AMP) significantly inhibits Ki67 and c-KIT expression in GIST-T1 tumor xenografts. Tumors were collected on the day after the last treatment and were then subjected to immunohistochemical detection of Ki67 and c-KIT expression. Representative images of immunohistochemical staining of Ki67 and c-KIT in mice tumors.

    Mol Cancer Ther, 2014, 13(10): 2276-87 . Fludarabine purchased from Selleck.

  • Normal human KC pretreated with STAT1 inhibitor (fludarabine [10 uM]) or STAT3 inhibitor (STA-21 [2 uM]) for 24 h. The mRNA levels of hBD2 and hBD3 were assessed by qRT-PCR.

    Mol Cell Biol 2014 34(24), 4368-78.. Fludarabine purchased from Selleck.

    Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 10 μM fludarabine. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.

    Int Immunopharmacol, 2016, 36:199-204.. Fludarabine purchased from Selleck.

製品安全説明書

STAT阻害剤の選択性比較

生物活性

製品説明 Fludarabineは血管平滑筋細胞の中に一種のSTAT1活性阻害剤で、一種のDNA合成阻害剤です。
ターゲット
STAT1 [4]
(Vascular smooth muscle cells)
体外試験

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  Mn7rSpVv[3Srb36gRZN{[Xl? M4rJcVIxKM7:TR?= NGC1ZY4zPCCq M4THV4lvcGmkaYTzJIV5eHKnc4Ppc44hd2ZiSVTP MYCyOVk1ODdzMh?=
MV-4-11 M4f6fGFxd3C2b4Ppd{BCe3OjeR?= MV[yMlUh|ryP MWG0PEBp M2fuWIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 NIXGe5ozPTFzMUW4Ny=>
THP-1 MX7BdI9xfG:|aYOgRZN{[Xl? MmDRNk42KM7:TR?= M1PWPVQ5KGh? NVfTSGc{cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> MlT4NlUyOTF3OEO=
MOLM 13 NVy4c21SSXCxcITvd4l{KEG|c3H5 NVHYW5V6Oi53IN88US=> M{jn[FQ5KGh? NFPBVJlqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NWjBS5BkOjVzMUG1PFM>
KBM3/Bu2506 MWfBdI9xfG:|aYOgRZN{[Xl? M17uXFIvPSEQvF2= M{LpdlQ5KGh? MYnpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NFjz[Y0zPTFzMUW4Ny=>
Nalm-6 NIj5WHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\4TWM2OD1zODFOwG0> M4\iXFI2ODZzMUCx
Reh NGTR[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT5XJRKSzVyPUOwJO69VQ>? NFzhPFMzPTB4MUGwNS=>
U2937 NVrPbZdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF4IN88US=> NY\ENoNlOjVyNkGxNFE>
Mec-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW4T|lKSzVy78{eOVAxKM7:TR?= Ml3HNlUxPjFzMEG=
RPMI-8226 MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTVyMDFOwG0> NVLhW4xzOjVyNkGxNFE>
Molt-4 M1PYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\IbWlEPTB;MUiwJO69VQ>? NGfUdo0zPTB4MUGwNS=>
Nalm-6-FluR MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Dx[mlEPTB;MkWwJO69VQ>? M4C1fFI2ODZzMUCx
Raji  MV\GeY5kfGmxbjDBd5NigQ>? MVKzxsDPxE1? MUeyOE81QC95MjDo MkLLbY5lfWOnczDhZ4N2dXWuYYTpc45{KG:oIIC1N{wheDZ|IHHu[EBxPzQEoB?= MYOyOFk1ODZ7NR?=
PBMC M1zNdWZ2dmO2aX;uJGF{e2G7 NVKxdotFPTBxMUCwJO69VQ>? NHLaSI4zPCCq NWrxVm05TE2VTx?= MljXbY5pcWKrdIOgV3RCXDFicHjvd5Bpd3K7bHH0bY9v NHHkWnIzPDlzMUi3Ni=>
MDA-231 MmGySpVv[3Srb36gRZN{[Xl? M3jnZVExOCEQvF2= MWOyOEBp MnqxSG1UVw>? MVrk[YNz\WG|ZYOgTWRQKGW6cILld5Nqd25? M2HSblI1QTFzOEey
624.38mel  NHnsWpBHfW6ldHnvckBCe3OjeR?= NX3wbZNYPTBizszN MnLJNlQhcA>? Ml\FSG1UVw>? NG\ae2Vl\WO{ZXHz[ZMhUUSRIHX4dJJme3Orb36= M2jDUVI1QTFzOEey
MDA-231 NEL3bpZHfW6ldHnvckBCe3OjeR?= NGDBNJk2OC1{MECg{txO NFv3cWMzPCCq M360emROW09? Mmn2bY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN? NF7SR3MzPDlzMUi3Ni=>
624.38mel  MYfGeY5kfGmxbjDBd5NigQ>? NXn4XVR2PTBvMkCwJO69VQ>? MmfPNlQhcA>? NUW0N293TE2VTx?= MWLpcohq[mm2czDJSG8h[WO2aY\peJkhcW6mZYDlcoRmdnSueTDv[kBuWk6DIHzleoVtew>? NYjwTpJQOjR7MUG4O|I>
HMECs MWTGeY5kfGmxbjDBd5NigQ>? NXyzcoViOTBywrFOwG3DqA>? MoHCN|bDqGh? Mn\SbY5pcWKrdIOgTWZP|rQEoHHu[EBNWFNiaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmURkGg[ZhxemW|c3nvci=> M1jwNFI1OjFzM{K3
HMECs  M2fVWWZ2dmO2aX;uJGF{e2G7 MWOxNFDDqM7:TdMg M{jlfFM3yqCq NH7TemNqdmirYnn0d{BKTk8QsdMgcYVlcWG2ZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJHNVSVRzIHHu[EBUXEGWMzygZpV1KG6xdDDv[kBUXEGWMh?= NH\ablUzPDJzMUOyOy=>
BJAB NYXoWnM2SXCxcITvd4l{KEG|c3H5 NUTDZ2V7PcLizszN M4O4WVI1KGh? NGHVSmlqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MnXKNlQxPTdzNEe=
I-83 MXPBdI9xfG:|aYOgRZN{[Xl? MkTGOeKh|ryP NWXVcnlrOjRiaB?= M4rHdolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MmjRNlQxPTdzNEe=
NALM6 NVH5eYp1SXCxcITvd4l{KEG|c3H5 NGnrPVc2yqEQvF2= Mkf4NlQhcA>? MWHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ Mn7kNlQxPTdzNEe=
DU-145 MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSwMVExKM7:Zz;tcC=> NIjsR2Y1QCCqwrC= NGXaR4pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYiyN|c{PDhzNR?=
Nalm-6 NVfTU5d{TnWwY4Tpc44hSXO|YYm= NUHxSWpHOTEEoN88US=> Mm\mNU8zNzRiaB?= NYDPPY5KcW6mdXPld{BifXSxcHjh[5k> Mn;1NlM3QDF{MkO=
Reh MVnGeY5kfGmxbjDBd5NigQ>? NYP0ZmV5OTEEoN88US=> M4PhN|EwOi92IHi= NIPER3ZqdmS3Y3XzJIF2fG:yaHHnfS=> M2S5UFI{PjhzMkKz
Nalm-6 M1z1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLoOlZEUUN3MDFijNwyOOLCid88US=> M{TMRlI{PjhzMkKz
Reh Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXuNWpXUUN3MDFijNwyOOLCid88US=> M{XreVI{PjhzMkKz
HEC1A NHnTVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO3NI1UOTByLUWwNEDPxE1? MnLLNlQhcA>? MmLzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1LOflI{PTl3Nkm3
AN3CA MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmxNFAuPTByIN88US=> NX3kOVQ1OjRiaB?= MlvGbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWizOIkxOjN3OUW2PVc>
HEC50B NYDCe5ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r5PVExOC13MECg{txO NX31bGcxOjRiaB?= M4fEOIlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 MVuyN|U6PTZ7Nx?=
HEC1A NGDiVotCeG:ydH;zbZMhSXO|YYm= NU\kPXlOOjBxMUCwJO69VQ>? M4G2[VI1KGh? M1jIZYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3zmc|I{PTl3Nkm3
AN3CA NX;w[VRVSXCxcITvd4l{KEG|c3H5 M1nkW|IxNzFyMDFOwG0> MV[yOEBp M{XFPYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MX[yN|U6PTZ7Nx?=
HEC50B M2PjWGFxd3C2b4Ppd{BCe3OjeR?= M2raeVIxNzFyMDFOwG0> NGTp[4ozPCCq NEHTRYZqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NVTP[WlYOjN3OUW2PVc>
EHEB NFLNWnJCeG:ydH;zbZMhSXO|YYm= NIH5[pM1OCEQvF2= NFr0epEzPCCq M1m2eolv\HWlZYOgZZBweHSxc3nz NEW1NY4zOzR7N{C3OS=>
A549 MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fBNWlEPTB;MUWuO:KyOi56INM1US=> M2nqOlI{Ozd5MUmy
A549 GAPDH-deficient NFrGcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLCTWM2OD1zOD61xtEzNjNiwsXN NX7nXI45OjN|N{exPVI>
CLL  M1fyOGFxd3C2b4Ppd{BCe3OjeR?= NXPJblE2OTBizszNxsA> MWiyOE06PiCq NH\ycVJqdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp NV\HN5JpOjJ{MEe2PFY>
MEC1 MnrpRZBweHSxc3nzJGF{e2G7 MmDqNVAxyqEQvF2= NHrUfZk4OiCq MVvpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MX6yNlE{Ojl5Mx?=
U937  NUHsOmFWSXCxcITvd4l{KEG|c3H5 MmLqNE45KM7:TR?= M4H1bFQuPDhiaB?= M4LmW4lv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MVuyNlA4PDdyMB?=
U937  MlO4RZBweHSxc3nzJGF{e2G7 NGex[lgyKM7:TR?= M3jpSFk3KGh? M4PSdolv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 NVPqdHRXOjJyMkO1NlM>
Daudi NGPK[HlCeG:ydH;zbZMhSXO|YYm= M{XmVlIxKM7:TR?= MYm5OkBp MoD2bY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= M{W0U|IzODJ|NUKz
J45.01 NWfRZmpSSXCxcITvd4l{KEG|c3H5 NFXy[HAyKM7:TR?= Mnn0PVYhcA>? NEK3fFJqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> MWmyNlAzOzV{Mx?=
RPMI 8226 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLlW|I3UUN3ME2yOU46yqEEsdMgN{44KM7:TR?= MkjFNlE6PDh{NkS=
CEM MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJwNNMgxtHDqDBwNDFOwG0> MnK5NlE6PDh{NkS=
Raji M1LMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInuW41KSzVyPUCuOFfDqMLzwrCwMlA1KM7:TR?= NYDGRYFUOjF7NEiyOlQ>
U937 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7oc5NKSzVyPUCuNlTDqMLzwrCwMlA1KM7:TR?= M{LyRVIyQTR6Mk[0
K562 NIjDcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwNEVCpOKyyqByLkC1JO69VQ>? M1TaVVIyQTR6Mk[0
NALM-6 MYXBdI9xfG:|aYOgRZN{[Xl? M3:3S|ExKM7:TdMg MnXNNlQhcA>? NVrFe|JxcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzcIlocHSueR?= NVLvN2YzOjF4OUmzPFM>
JMV-3 MnLjRZBweHSxc3nzJGF{e2G7 NFfRWZkyOCEQvF5CpC=> NGf1ZlEzPCCq NFi1UHhqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPsbYdpfGy7 M1nuZlIyPjl7M{iz
EHEB MnTiSpVv[3Srb36gRZN{[Xl? NG\yW3U2NTVyIN88US=> NVfYRXZSOjRiaB?= MVnk[YNz\WG|ZYOgdFIyKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> NIjEfmQzOTF4OEO5NS=>
JVM-2  NGXlRpNHfW6ldHnvckBCe3OjeR?= NH7PTpQ{OCEQvF2= NXHPXFBWOjRiaB?= M3WwfoRm[3KnYYPld{BxOjFiZYjwdoV{e2mxbh?= NIf5VY8zOTF4OEO5NS=>
KBM3/Bu2506 MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnMcIVKSzJyPUCuOlchyrWP M2nGV|IxQTN|NUC5
KBM3/Bu2506 M{PqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL1W5YxNjZizszN NH;5fpEzPCCq NXnwbFRCcW6lcnXhd4V{KHSqZTDj[YxtKG[{YXP0bY9vKGmwIGOtdIhie2V? NYXTVHYyOjB7M{O1NFk>
MDA-MB-231 NIrkPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHxTWM2OD12LkCg{txO MmrWNlA1PDd|OUC=
MCF-7 M13HUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO4[odjUUN3ME2xOU4xKM7:TR?= MV6yNFQ1PzN7MB?=
HLE-B3  Mm\USpVv[3Srb36gRZN{[Xl? NIDFe|EzPSEQvF2= MUm0PEBp M2S3WoJtd2OtczDJSm4u|rQkgKPpcoR2[2WmIGPURXQyKHCqb4PwbI9zgWyjdHnvckBidmRiSVTPJIV5eHKnc4Ppc44> M4XCb|IxPDN3MUW4
K562 NW[5N2E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXK3NkBp NHTiS3NKSzVyPUOuN{BvVQ>? NXX0dGVUOjB|MEexPVg>
BW-225 NYrz[ZpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\lNGlEOjB;MT6zO{DEnzFy4pkSPOKh|ryPwrC= M2L3VlE5PjZzM{iw
OH-65 NHjZVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\4TWMzOD1zLkO3JOOYOTEkiKK4xsDPxE4EoB?= MV2xPFY3OTN6MB?=
GR-145 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|IxRTJwN{Sgx7chOTEkiKK4JEDPxE4EoB?= NGnodVIyQDZ4MUO4NC=>
A549 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLsb2hKSzJyPUWuOFghy5diMUFijLI5KM7:TdMg NFW2b2gyQDZ4MUO4NC=>
CaSki  NX;FT5hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NICySWlKSzJyPUGuN|chy5diMUFijLI4KM7:TdMg M4L1b|E5PjZzM{iw
ZMK-1 M1;leWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDnZ3djUUN{ME2xMlM4KMPZIEGw5qiTPiEQvF5CpC=> M3nKelE5PjZzM{iw
SKW6.4 MnX2RZBweHSxc3nzJGF{e2G7 M1;MeFAvODFvMUCg{txO MWGyOE81QCCq MkDRbY5lfWOnczDj[YxtKGSnYYToJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? MVGxPFA6OjN2MB?=
RPMI 8226 M{TIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTvUJUzPCCq NVnMS4lYUUN3ME2xMlU1yqEQvF2= NWq4T3ZYOTd7N{[xPFY>
MM.1S NXThSZJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfzVmk1QCCq MUjJR|UxRTF|LkS4xsDPxE1? M3;QV|E4QTd4MUi2
MM.1R NXTSVG5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L4d|Q5KGh? MonpTWM2OD1|Mz63PUDPxE1? NUTxeoR[OTd7N{[xPFY>
U937 M1u2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LJeGlEPTB;MzyyNFAhyrFiNU[wJI5O MVSxOVk{ODN4MR?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • 濃度: 2 μg/mL
  • 反応時間: 24 hours
  • 実験の流れ:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • 製剤: PBS
  • 投薬量: 40 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 285.23
化学式

C10H12FN5O4

CAS No. 21679-14-1
保管
別名 FaraA, Fludarabinum

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01585415 Terminated Metastatic Cancer|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 9, 2012 Phase 1
NCT01503242 Recruiting Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) January 9, 2012 Phase 1
NCT01319565 Active, not recruiting Metastatic Melanoma|Skin Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 9, 2011 Phase 2
NCT01145209 Active, not recruiting Small Lymphocytic Lymphoma|CLL (Chronic Lymphocytic Leukemia) National Heart, Lung, and Blood Institute (NHLBI)|University of Virginia|GlasoSmithKline|National Institutes of Health Clinical Center (CC) June 9, 2010 Phase 2
NCT02500576 Recruiting Melanoma M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.|Prometheus Inc. August 7, 2015 Phase 2
NCT01174121 Recruiting Metastatic Colorectal Cancer|Metastatic Gastric Cancer|Metastatic Pancreatic Cancer|Metastatic Hepatocellular Carcinoma|Metastatic Cholangiocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2010 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • 回答:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT信号経路図

相関STAT製品

Tags: Fludarabineを買う | Fludarabine ic50 | Fludarabine供給者 | Fludarabineを購入する | Fludarabine費用 | Fludarabine生産者 | オーダーFludarabine | Fludarabine化学構造 | Fludarabine分子量 | Fludarabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID